ASX:HLS

Healius (HLS) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.33 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
4.46%
Price Target
N/A
HLS stock logo

About Healius Stock (ASX:HLS)

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

HLS Stock News Headlines

Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Healius Ltd HLS
Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Healius share price rallies amid corporate reset
This equity raise looks extremely attractive
Why are Healius shares crashing 35% on Wednesday?
Healius Limited
HLS.AX - Healius Limited
See More Headlines
Receive HLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Healius and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2019
Today
4/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
10,500
Year Founded
N/A

Profitability

Net Income
$-984,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.69 billion
Book Value
A$1.45 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.65
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Paul D. Anderson
    MD, Group CFO, CEO & Director
  • Mr. John McKechnie
    Advisor
  • Dr. Jan Van Rooyen
    Head & Group Executive of Healius Pathology
  • Dr. Phil Lucas
    Chief Executive of Lumus Imaging
  • Ian Mcphan
    Chief Operating Officer of Healius Pathology
  • Sharon Ng
    Head of Group FP&A
  • Ms. Mary Ellen Weaver AGIA
    Company Secretary
  • Dr. John Houston
    Advisor

HLS Stock Analysis - Frequently Asked Questions

How were Healius' earnings last quarter?

Healius Limited (ASX:HLS) released its quarterly earnings results on Friday, February, 15th. The company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.09 by $0.06. Healius had a negative net margin of 57.63% and a negative trailing twelve-month return on equity of 68.02%.

Is Healius a good dividend stock?

Healius (ASX:HLS) pays an annual dividend of A$0.12 per share and currently has a dividend yield of 4.46%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for HLS.

What other stocks do shareholders of Healius own?
This page (ASX:HLS) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners